Here are four things to know:
1. Dallas-based Hodges acquired 186,425 shares of NuVasive’s stock, which is valued at approximately $12,558,000 in the fourth quarter of 2016.
2. NuVasive’s shares traded down 1.94 percent earlier this week, reaching $69.32.
3. The company’s 12-month low is $36.81 and their 12-month high is $71.10. Its 50-day moving average price is $67.96 and its 200-day moving average price is $64.80.
4. NuVasive creates minimally disruptive surgical products and works on developing solutions for spinal ailments.
More articles on devices:
WishBone hires former Congressman Marlin Stutzman as president — 4 takeaways
Mainstay Medical’s first ReActiv8 implanted in Germany — 5 observations
Medtronic plans to sell medical supplies unit, Bloomberg reports: 6 key insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
